Delivery Order SPE2DB20D2104-SPE2DB25FMWPU
- Not listed
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 0.5 mg tablets (30-count) with a ceiling value of $1,952.46. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive process. The contract is due for completion by August 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child order under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $13,867.55 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units). This firm fixed-price delivery order, executed on December 4, 2025, with completion targeted for December 5, 2025, represents a competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,407.85 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count) on September 17, 2025, with an ultimate completion date of September 18, 2025. This firm fixed-price delivery order represents a non-competitive award issued under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle that enables comprehensive...
- The Defense Logistics Agency awarded a delivery order valued at $17,662.12 to AmerisourceBergen Drug Corp for the supply of Rexulti 0.5 mg tablets (30-count units) under a firm fixed-price contract. The award was made on October 28, 2025, with an ultimate completion date of October 29, 2025. This non-competitive delivery order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary distribution...
- The Defense Logistics Agency awarded a delivery order valued at $11,846.76 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed price contract. The award, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this pharmaceutical delivery order and functions as a...
- The Defense Logistics Agency awarded a delivery order valued at $5,534.04 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count packages) under a firm fixed-price contract. This non-set-aside award was issued on December 3, 2025, with an ultimate completion date of December 4, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and primary distribution center for federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $30,339.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed price arrangement. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's larger contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Rexulti 0.5 mg tablets in a quantity of 30 units, with a ceiling value of $1,597.63. This firm fixed-price delivery order is set to be completed by October 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition without any set-aside designation, reflecting...
- The Defense Logistics Agency awarded a delivery order valued at $9,608.75 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count packaging) on April 23, 2025, with completion scheduled for April 24, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and represents a small-value pharmaceutical transaction under the company's existing contract vehicle with DLA. The product will be delivered to AmerisourceBergen's facility...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMWPUDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Rexulti 0.5 mg tablets (30-count packaging) under a firm fixed-price contract with a ceiling value of $4,909.13. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and does not utilize a set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order demonstrates AmerisourceBergen's role as a critical pharmaceutical vendor within the DLA Medical Supply Chain, supplying medications and medical products to support military and federal healthcare systems globally. Rexulti, an antipsychotic medication used in treating psychiatric conditions, represents one of many brand-name and specialty pharmaceuticals delivered by the contractor under its comprehensive prime vendor agreement. The competitively awarded IDC vehicle enables flexible procurement of diverse pharmaceutical products across multiple therapeutic domains to support the Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 7/28/25 |